Evidence map›Paper›PMID 37978401›Full record

ArticleImmunity & ageing : I & A2023

Immunological and senescence biomarker profiles in patients after spontaneous clearance of hepatitis C virus: gender implications for long-term health risk.

Rubén Martín-Escolano, Erick Joan Vidal-Alcántara, Javier Crespo, Pablo Ryan, Luis Miguel Real, Juan Ignacio Lazo-Álvarez, Joaquín Cabezas-González, Juan Macías, María Teresa Arias-Loste, Guillermo Cuevas and 5 more

Open access · goldAbstract read
In one paragraph

Article in Immunity & ageing : I & A, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 1 country.

Rubén Martín-EscolanoUnidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda), Carretera Majadahonda- Pozuelo, Km 2.2, Madrid, Majadahonda, 28220, Spain.
Erick Joan Vidal-AlcántaraUnidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda), Carretera Majadahonda- Pozuelo, Km 2.2, Madrid, Majadahonda, 28220, Spain.
Javier CrespoGastroenterology and Hepatology Department, Clinical and Traslational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, Santander, Spain.
Pablo RyanCentro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Luis Miguel RealCentro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Juan Ignacio Lazo-ÁlvarezInternal Medicine Service, Hospital Universitario Infanta Leonor, Facultad de Medicina, Universidad Complutense de Madrid, Gregorio Marañón Health Research Institute, Madrid, Spain.
Joaquín Cabezas-GonzálezGastroenterology and Hepatology Department, Clinical and Traslational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, Santander, Spain.
Juan MacíasCentro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
María Teresa Arias-LosteGastroenterology and Hepatology Department, Clinical and Traslational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, Santander, Spain.
Guillermo CuevasInternal Medicine Service, Hospital Universitario Infanta Leonor, Facultad de Medicina, Universidad Complutense de Madrid, Gregorio Marañón Health Research Institute, Madrid, Spain.
Ana Virseda-BerdicesUnidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda), Carretera Majadahonda- Pozuelo, Km 2.2, Madrid, Majadahonda, 28220, Spain.
Veronica BrizLaboratory of Reference and Research On Viral Hepatitis, National Center for Microbiology, Institute of Health Carlos III, Madrid, Majadahonda, Spain.
Salvador Resino *Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda), Carretera Majadahonda- Pozuelo, Km 2.2, Madrid, Majadahonda, 28220, Spain.
María Ángeles Jiménez-Sousa *Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda), Carretera Majadahonda- Pozuelo, Km 2.2, Madrid, Majadahonda, 28220, Spain. jimenezsousa@isciii.es.
Amanda Fernández-Rodríguez *Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda), Carretera Majadahonda- Pozuelo, Km 2.2, Madrid, Majadahonda, 28220, Spain. amandafr@isciii.es.
Instituto de Salud Carlos III · ESCentro Nacional de Microbiologia · ESCentro de Investigación Biomédica en Red · ESCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESHospital Universitario Infanta Leonor · ESInstituto de Investigación de Enfermedades Raras · ESMarqués de Valdecilla University Hospital · ESUniversidad Complutense de Madrid · ES

Funding

Consorcio Centro de Investigación Biomédica en Red CB 2021Fundación Universidad Alfonso X el Sabio 1.010.932Instituto de Salud Carlos III CP14/0010Instituto de Salud Carlos III CP17CIII/00007Ministerio de Ciencia e Innovación CB21/13/00044Ministerio de Ciencia e Innovación FJC2020-042865-IMinisterio de Ciencia e Innovación PID2021-126781OB-I00
6 · The paper itself

Abstract

backgroundAbout 25% of patients with acute hepatitis C virus (HCV) infection show spontaneous clearance within the first six months of infection but may remain at risk of inflammaging, aging, and liver and non-liver disease complications. This study evaluated the differences in the plasma levels of immune checkpoints (ICs) and senescence-associated secretory phenotype (SASP) biomarkers between patients who had spontaneously eliminated HCV infection (SC group) and individuals without evidence of HCV infection (C group).

methodsWe performed a multicenter retrospective study of 56 individuals: 32 in the SC and 24 in the C groups. ICs and SASP proteins were analyzed using a Luminex 200TM analyzer. The statistical analysis used Generalized Linear Models with gamma distribution (log-link) adjusted by significant variables and sex.

results13 ICs (BTLA, CD137(4-1BB), CD27, CD28, CD80, GITR, HVEM, IDO, LAG-3, PD-1, PD-L1, PD-L2, and TIM-3) and 13 SASP proteins (EGF, Eotaxin, IL-1alpha, IL-1RA, IL-8, IL-13, IL-18, IP-10, SDF-1alpha, HGF, beta-NGF, PLGF-1, and SCF) were significantly higher in SC group after approximately more than two years of HCV clearance. After stratifying by sex, differences remained significant for males, which showed higher levels for 13 ICs and 4 SASP proteins in SC. While only PD-L2 was significantly higher in SC women, and no differences in SASP were found.

conclusionsHigher plasma levels of different IC and SASP proteins were found in individuals after more than two years of HCV clearance, mainly in men. Alterations in these molecules might be associated with an increased risk of developing liver and non-hepatic diseases.

Indexed as

BiomarkersHCVImmune checkpoint proteinsSASP proteinsSpontaneous clearance

Identifiers

PMID37978401
PMCPMC10655350
OpenAlexW4388769557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.